Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study-Reference-Cited by-同舟云学术

Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer – a retrospective multicentre study

Published:2019-08-28 Issue:10 Volume:139 Page:918-925
ISSN:0001-6489
Container-title:Acta Oto-Laryngologica
language:en
Short-container-title:Acta Oto-Laryngologica

Author:

Okamoto Isaku¹,Sato Hiroki¹,Kondo Takahito²,Koyama Nobuyuki³,Fushimi Chihiro⁴,Okada Takuro⁴,Miura Kouki⁴,Matsuki Takashi⁵,Yamashita Taku⁵,Omura Go⁶,Tsukahara Kiyoaki¹

Affiliation:

1. Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;

2. Department of Otolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan;

3. Department of Clinical Oncology, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan;

4. Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan;

5. Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan;

6. Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan

Publisher

Informa UK Limited

Subject

Otorhinolaryngology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00016489.2019.1648867

Reference19 articles.

1. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

2. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology, Head and Neck Cancers (Version 1.2019).

3. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

4. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

5. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG);European Archives of Oto-Rhino-Laryngology;2024-05-25

2. The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland;Clinical Oncology;2024-05

3. The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK;International Journal of Cancer;2024-04-29

4. Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience;Current Oncology;2023-09-29

5. Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer;The Laryngoscope;2023-06-28